We are live on ! Find out more
INM icon

InMed Pharmaceuticals
INM

7 hedge funds and large institutions have $877K invested in InMed Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,292% more capital inflows, than outflows

Capital inflows: $877K | Capital outflows: $63K

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

17% more funds holding

Funds holding: 6 → 7 (+1)

11.01% more ownership

Funds ownership: 7.49% → 18.5% (+11%)

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
1
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Armistice Capital
Armistice Capital
New York
+$479K
2
SM
Sabby Management
Florida
+$141K
3
Millennium Management
Millennium Management
New York
+$129K
4
Bank of America
Bank of America
North Carolina
+$62.9K
5
UBS Group
UBS Group
Switzerland
+$53.6K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$23K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$23K
3
Citadel Advisors
Citadel Advisors
Florida
-$6K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$6K
5
Creative Planning
Creative Planning
Kansas
-$5K

INM Hedge Fund Activity: Q3 2022 in Review

7 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q3 2022, worth a combined $877K — up 70% from $515K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new INM positions and 5 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, adding an estimated $479K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $23K sold.

  • 7 institutional investors held InMed Pharmaceuticals (INM) as of Q3 2022, up from 6 in Q2 2022.
  • Funds reported $877K of InMed Pharmaceuticals stock for Q3 2022, up 70% quarter-over-quarter.
  • 6 funds opened new InMed Pharmaceuticals positions in Q3 2022 and 5 closed out, a net change of +1 holder.
  • The largest InMed Pharmaceuticals buyer in Q3 2022 was Armistice Capital, an estimated $479K added.
  • The largest InMed Pharmaceuticals seller in Q3 2022 was Renaissance Technologies, an estimated $23K sold.

Based on aggregated 13F filings for Q3 2022.